| Popis: |
Objective To evaluate the clinical effectiveness, tolerability, and impact on quality of life of Hymovis in the conservative treatment of overuse cartilage lesions due to osteoarthritis and/or meniscus tears. Patients and methods: Non-interventional, prospective, descriptive, observational, multicenter study of 165 patients aged over 18 years with osteoarthritis and/or a meniscus tear treated with two injections of Hymovis. Follow-up visits were held at 10 days and at 1, 2, and 3 months for all patients and at 6 months for patients with osteoarthritis with or without a meniscus tear. Clinical and functional parameters were collected at each participating clinic and patients also completed the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Results Patients in all three groups (osteoarthritis, meniscus tear, and osteoarthritis plus meniscus tear) reported a marked and significant reduction in pain after treatment with Hymovis. At 6 months, patients with osteoarthritis and combined lesions showed improvements of the signs and symptoms associated with the pathology. Patients with only OA showed also improvement in palpation, mobility, and joint movement parameters. Patients in the meniscus tear group showed improvements in physical examination, clinical manoeuvre, and joint movement parameters. Additional improvements were observed for quality of life, activities of daily living, and sport and recreation. Satisfaction with treatment was very high, with 85% of osteoarthritis patients reporting considerable or very considerable improvement. None of the patients reported any severe adverse effects. Conclusions Hymovis is a safe and effective option for the conservative treatment of overuse cartilage lesions in the knee due to osteoarthritis and/or meniscus tears. |
